Higher Guanfacine Doses Found Effective for Adolescent ADHD

While stimulants generally remain first-line medication for ADHD, alternatives are often needed due to side effects or ineffectiveness.   Of the non-stimulant medications, guanfacine and its more recent extended release preparation (trade name Intuniv) is one possible alternative.  Current FDA guidelines specify 4mg per day as the maximum dose, although much of this recommendation is based on […]

Tags: , , ,

Very High Rates of Psychotic Symptoms Linked to Stimulant Medications

(Note: portions of this review were recently published in an article in Clinical Psychiatry News) While it is known that stimulant medications used to treat ADHD might occasionally to lead to psychotic symptoms, this side effect is considered to be rare and usually associated with either medication abuse or very high dosages.  A report just released today […]

Tags: , , , , ,

What Happened to Concerta?

There is quite a bit of confusion out there about the supply and availability of one of the staple ADHD medications, Concerta, which is the brand name of a long acting preparation of methylphenidate that uses a novel delivery system called OROS (Osmotic [Controlled] Release Oral [Delivery] System) to deliver the medication gradually throughout the […]

Tags: , , , ,

ADHD Medications and School Performance

The Wall Street Journal recently published an article casting doubt about the ability of ADHD medications to improve school grades and achievement.  Actually, casting doubt might be a little soft as the title was “ADHD Drugs Don’t Boost Grades.”  In the article, the author runs through a number of studies (some not published) that find […]

Tags: , , ,

Who Should Evaluate and Treat ADHD? The AAP’s Nudge

In October, the journal Pediatrics, based right here in Vermont, published updated guidelines from the American Academy of Pediatrics (AAP) regarding the assessment and treatment of ADHD.   Since its publication, what has clearly generated the most media discussion about these new guidelines is the inclusion of preschool children (age 4 and above) in the recommendations.  […]

Tags: , , ,

New NEJM Study Shows No Increased Cardiovascular Risk with ADHD Medications

by John Koutras, MD The use of ADHD drugs was not associated with an increased risk of serious cardiovascular events in children and young adults.  This was the overall finding of a new study published in the New England Journal of Medicine.  ADHD medications are prescribed for more than 2.7 million children in the US […]

Tags: ,